BRAF and cutaneous melanoma: A recent phase IIa trial evaluated the efficacy and safety of dabrafenib plus trametinib in 77 East Asian patients with unresectable or metastatic BRAF V600-mutant cutaneous melanoma, including 61 (79.2%) from China’s mainland.